Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:

• Introduction (00:00)
• Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
• Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
• Strategies to Prevent and Manage Hyperglycemia (27:02)
• Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
• Mitigation and Management of Gastrointestinal Adverse Events (51:05)
• Management of Dermatologic Adverse Events (59:58)
• Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
• Monitoring and Management of Cytopenias (1:21:23)

CME information and select publications

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:

• Introduction (0:00)
• Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17)
• Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24)
• Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28)
• Management of Limited-Stage SCLC — Dr Ganti (1:31:54)

CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:

• Introduction (0:00)
• HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)
• Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54)
• Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:

• Introduction (0:00)
• Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
• Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
• Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
• Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
• Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)

CME information and select publications

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:

• Introduction: Relative Impact of Targeted Treatment (00:00)
• HER2 Alterations (8:04)
• KRAS Mutations (24:25)
• MET Overexpression (30:34)
• ALK Fusions (32:34)
• ROS1 Fusions (42:36)
• RET Fusions (52:00)

CME information and select publications

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:

• Introduction (0:00)
• Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
• Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
• Utility of Belantamab Mafodotin in R/R MM (49:29)
• Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications

Featuring an interview with Dr Ramez Eskander, including the following topics:

• Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)
• Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)
• Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)
• Current and investigational targets of ADCs in gynecologic cancers (17:14)
• Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)
• Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)
• Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)
• Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)
• Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)

CME information and select publications

Featuring perspectives from Dr Joshua K Sabari, including the following topics:

• Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)
• Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study. ESMO 2025;Abstract 2020P. (8:30)
• Schram AM et al. Beamion PANTUMOR-1: Rationale and design of a phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol 2026;22(7):795-803. (12:53)
• Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654. (19:40)
• Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648. (21:41)
• Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137. (22:59)
• Jänne PA et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic NSCLC with or without brain metastases: A secondary analysis of randomized clinical trials. JAMA Netw Open 2025;8(11):e2543107. (24:37)

CME information and select publications

Featuring perspectives from Dr Joshua K Sabari, including the following topics:

• Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00)
• Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG-1. ESMO 2025;Abstract LBA74. (5:25)
• Le X et al. Sevabertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med 2025;393(18):1819-32. (12:37)

CME information and select publications

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:

• Introduction (00:00)
• Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
• Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
• Adjuvant CDK4/6 Inhibitor Therapy (17:14)
• Practical Considerations with CDK4/6 Inhibitors (29:57)
• Monitoring and Management of Cytopenias (42:02)
• CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
• Management of Gastrointestinal Adverse Events (1:03:47)
• CDK4/6 Inhibitors in Unique Populations (1:10:41)
• Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)

CME information and select publications